Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 4/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.49 |
| ▸ | NPC1 | O15118 | 1/20 | 0.46 |
| ▸ | CMA1 | P23946 | 8/20 | 0.44 |
| ▸ | FKBP4 | Q02790 | 1/20 | 0.42 |
| ▸ | MMP8 | P22894 | 2/20 | 0.41 |
| ▸ | MMP3 | P08254 | 1/20 | 0.41 |
| ▸ | ELANE | P08246 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.41 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.40 |
| ▸ | TACR1 | P25103 | 1/20 | 0.40 |
| ▸ | CTRC | Q99895 | 2/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6523783 | 0.91 | CMA1 (0.48) | MEN1KMT2ANPC1CMA1ELANE | |
| SCHEMBL5850980 | 0.91 | FKBP4 (0.48) | MEN1KMT2ACMA1FKBP4TACR1 | |
| SCHEMBL7277525 | 0.88 | TACR1 (0.43) | MEN1KMT2AFKBP4ELANELMNA | |
| SCHEMBL10404955 | 0.87 | KMT2A (0.47) | MEN1KMT2ANPC1CMA1FKBP4 | |
| SCHEMBL8001618 | 0.87 | LMNA (0.47) | KMT2ANPC1FKBP4MMP3ELANE | |
| SCHEMBL7126199 | 0.86 | KMT2A (0.44) | MEN1KMT2ANPC1FKBP4MMP3 | |
| SCHEMBL9666984 | 0.86 | LMNA (0.48) | MEN1KMT2ACMA1ELANELMNA | |
| SCHEMBL8010107 | 0.84 | FKBP4 (0.46) | MEN1KMT2AFKBP4ELANELMNA | |
| SCHEMBL27824844 | 0.81 | LMNA (0.48) | MEN1KMT2ANPC1LMNANPSR1 | |
| SCHEMBL1296384 | 0.81 | LMNA (0.48) | MEN1KMT2ANPC1LMNANPSR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 79 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4005589-B1 | A CONTROLLED RELEASE ENZYMATIC COMPOSITION AND METHODS OF USE | MARIZYME INC (US) | 2024-04-10 | — | — | EP | disclosed |
| EP-4005589-A1 | A CONTROLLED RELEASE ENZYMATIC COMPOSITION AND METHODS OF USE | Marizyme, Inc. (US) | 2022-06-01 | — | — | EP | disclosed |
| EP-2144625-B1 | A CONTROLLED RELEASE ENZYMATIC COMPOSITION AND METHODS OF USE | MARIZYME INC (US) | 2022-02-09 | — | — | EP | disclosed |
| US-8283344-B2 | Method of treating inherited severe neutropenia | MERCK & CO., INC. (US) | 2012-10-09 | — | — | US | disclosed |
| US-7947270-B2 | Using multifunctional enzyme having chymotrypsin, trypsin, elastase, collagenase and/or exopeptidase activity | ARCIMBOLDO AB (SE) | 2011-05-24 | — | — | US | disclosed |
| US-20110059960-A1 | METHOD OF TREATING INHERITED SEVERE NEUTROPENIA | MERCK SHARP & DOHME LLC | 2011-03-10 | — | — | US | disclosed |
| EP-2203059-A1 | METHOD OF TREATING INHERITED SEVERE NEUTROPENIA | Merck Sharp & Dohme Corp. (US) | 2010-07-07 | — | — | EP | disclosed |
| WO-2009035541-A1 | METHOD OF TREATING INHERITED SEVERE NEUTROPENIA | MERCK & CO., INC. (US) | 2009-03-19 | — | — | WO | disclosed |
| US-20060134641-A1 | Treating viral infections with krill enzymes | ARCIMBOLDO AB (SE) | 2006-06-22 | — | — | US | disclosed |
| US-20050025722-A1 | Using multifunctional enzyme having chymotrypsin, trypsin, elastase, collagenase and/or exopeptidase activity | ACB HOLDING AB (SE) | 2005-02-03 | — | — | US | disclosed |
| US-4680391-A | Substituted azetidinones as anti-inflammatory and antidegenerative agents | MERCK & CO., INC. (US) | 1987-07-14 | — | — | US | disclosed |
| US-4637999-A | PROTEASE INHIBITORS | MERCK & CO., INC. (US) | 1987-01-20 | — | — | US | disclosed |
| EP-0207447-A2 | Tetrazolyl derivatives of beta-lactams useful as elastase inhibitors | MERCK & CO. INC. (US) | 1987-01-07 | — | — | EP | disclosed |
| US-4623645-A | ELASTASE INHIBITORS | MERCK & CO., INC. (US) | 1986-11-18 | — | — | US | disclosed |
| EP-0199630-A1 | Substituted azetidinones, pharmaceutical compositions containing them, and their use for the manufacture of anti-inflammatory and antidegenerative medicaments | MERCK & CO. INC. (US) | 1986-10-29 | — | — | EP | disclosed |
| EP-0170192-A1 | Penicillin derivatives as anti-inflammatory and antidegenerative agents | MERCK & CO. INC. (US) | 1986-02-05 | — | — | EP | disclosed |
| US-4547371-A | Substituted cephalosporin sulfones as anti-inflammatory and anti-degenerative agents | MERCK & CO., INC. (US) | 1985-10-15 | — | — | US | disclosed |
| US-4495197-A | N-Carboxyl-thienamycin esters and analogs thereof as anti-inflammatory agents | MERCK & CO., INC. (US) | 1985-01-22 | — | — | US | disclosed |
| US-4493839-A | 1-Carbapenem-3-carboxylic esters as anti-inflammatory agents | MERCK & CO., INC. (US) | 1985-01-15 | — | — | US | disclosed |
| US-4465687-A | ANTIARTHRITIC AGENT, ENZYME INHIBITOR | MERCK & CO., INC. (US) | 1984-08-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110059960-A1 | METHOD OF TREATING INHERITED SEVERE NEUTROPENIA | SCN1B, SCNN1B, SCNN1A | MEN1 832/4885KMT2A 1562/4885NPC1 191/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.